Group 1 - Xiansheng Pharmaceutical expects a net profit increase of 80.1% to 93.9% for the fiscal year 2025, with projected revenue of approximately RMB 7.7 billion to 7.8 billion, reflecting a year-on-year growth of about 16.0% to 17.6% [1] - The growth in revenue and profit is attributed to increased income from innovative drugs, licensing income, and net gains from the fair value of the investment portfolio [1] Group 2 - GSK has announced the acquisition of 35Pharma for $950 million in cash, gaining access to an early-stage hypertension drug asset, HS235, which has completed Phase I clinical trials [2] - This acquisition marks GSK's expansion into the cardiovascular drug sector, addressing financial pressures from expiring patents on key HIV drugs [2] Group 3 - BioMarin has decided to withdraw its gene therapy Roctavian for hemophilia A from the market after failing to find a buyer, with sales of only $26 million in 2024 and a slight increase to $36 million in 2025 [3] - The withdrawal highlights challenges in the high-value rare disease drug market, including competition and reimbursement difficulties [3] Group 4 - Sanofi's new drug application for SSGJ-611, a humanized monoclonal antibody for atopic dermatitis, has been accepted by the National Medical Products Administration, with promising results from Phase III clinical trials [4] - The prevalence of atopic dermatitis has been increasing globally, with a reported adult prevalence rate of 6.1% in China, which may boost investor confidence [4] Group 5 - Novo Nordisk announced that its weight loss drug Wegovy will be sold at half price in the U.S. starting January 1, 2027, with a unified wholesale price of $675 for its GLP-1 product line [5] - The price reduction aims to lower patient out-of-pocket costs and make the drug more accessible, while also addressing increasing market competition [5]